Skandinaviska Enskilda Banken AB publ Acquires 62,956 Shares of AbbVie Inc. $ABBV

Skandinaviska Enskilda Banken AB publ raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.1% in the third quarter, HoldingsChannel.com reports. The firm owned 947,375 shares of the company’s stock after buying an additional 62,956 shares during the period. AbbVie comprises 0.9% of Skandinaviska Enskilda Banken AB publ’s holdings, making the stock its 18th largest position. Skandinaviska Enskilda Banken AB publ’s holdings in AbbVie were worth $219,564,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Hill Island Financial LLC raised its holdings in shares of AbbVie by 4.4% in the 3rd quarter. Hill Island Financial LLC now owns 1,175 shares of the company’s stock worth $272,000 after acquiring an additional 50 shares during the last quarter. Southeast Asset Advisors LLC increased its holdings in AbbVie by 63.0% during the 3rd quarter. Southeast Asset Advisors LLC now owns 25,311 shares of the company’s stock worth $5,861,000 after purchasing an additional 9,782 shares in the last quarter. Summitry LLC increased its holdings in AbbVie by 34.9% during the 3rd quarter. Summitry LLC now owns 4,110 shares of the company’s stock worth $952,000 after purchasing an additional 1,064 shares in the last quarter. Pitti Group Wealth Management LLC bought a new position in shares of AbbVie in the third quarter valued at approximately $237,000. Finally, Swan Global Investments LLC purchased a new position in shares of AbbVie during the third quarter valued at approximately $324,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on ABBV. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Evercore reduced their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Piper Sandler reissued an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Finally, Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $231.57 on Tuesday. The company has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The company’s 50-day moving average is $223.73 and its 200 day moving average is $221.37. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.